|Bid||0.00 x 1100|
|Ask||3.85 x 1000|
|Day's Range||3.1800 - 3.3000|
|52 Week Range||0.8200 - 4.4400|
|Beta (3Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.00|
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 months. As of October 22, 2018, CEL-SCI had 28,271,615 outstanding shares of common stock. "We have raised $20 million this year as we are nearing the date for the final data readout on our pivotal, global Phase 3 study in head and neck cancer," stated CEL-SCI's Chief Executive Officer Geert Kersten.
Nearing the end of its long running Phase III trial for squamous cell carcinoma of the head and neck (SCCHN), CEL-SCI (CVM) has experienced several recent catalysts that have returned attention and interest to their novel immuno-oncology program. In June an arbitrator promulgated a final ruling in favor of CEL-SCI’s claims that their previous contract research organization (CRO) had breached the contract related to the timely enrollment of the Multikine Phase III trial. Combined with the lifting of an FDA clinical hold in August 2017, the arbitration resolution allowed management’s primary focus to return to the Phase III primary head and neck cancer study.
Blue chips led broad price action in September, lifting the S&P 500 and the Dow Jones Industrial Average to bull market highs while small cap indices such as the Russell 2000 pulled back in shallow declines. Penny and low-priced stocks held up well during the month despite this headwind, with traders scooping up junior energy plays in reaction to a surging crude oil market. Penny stock buyers have taken notice, lifting the shares of low-priced American oil and gas companies still reeling from the group's historic decline into 2016.
CEL-SCI Corporation (NYSE American: CVM) is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018. The NYSE has notified CEL-SCI that trading in the warrants on the NYSE American will be suspended after the close of business on October 8, 2018 to ensure all trades in the warrants settle in time to allow the purchasers of such warrants to exercise the warrants on or before the Expiration Date.
HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.
CEL-SCI Corporation (NYSE American: CVM) announced today it has received $5,435,367 through the exercise of warrants to purchase shares of the Company's common stock during August through September 13, 2018. As of September 13, 2018, CEL-SCI had 27,351,324 outstanding shares of common stock. “We are pleased that warrant holders see the value of CEL-SCI’s common stock and have chosen to exercise their warrants.
CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019. LEAPS has been specifically selected by the NIH for the Commercialization Transition Track, which provides technical assistance to awardee companies to move NIH-funded technologies towards commercialization and market readiness.
NEW YORK, NY / ACCESSWIRE / August 22, 2018 / U.S. markets continue to edge higher on Tuesday as optimism over trade talks and upbeat earnings pushed equities into the green. Additionally, the Federal ...
Our singular goal right now is to reach the final data readout of the Phase 3 trial to establish the utility of our investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer. Based on published survival data, we believe top line results may be available as soon as early 2019. The results of the Phase 3 study, if positive, will form the basis of our regulatory submissions for marketing applications worldwide to commercially market and distribute Multikine.
CEL-SCI Corporation (NYSE American: CVM) announces that the NYSE American (the “Exchange”) has accepted the Company’s plan to bring itself into compliance with the Exchange's continued listing standards. The Company previously received notice from the Exchange on July 12, 2018, indicating the Company is below compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) since it reported a stockholders’ equity deficit as of June 30, 2018 and had net losses in its 5 most recent fiscal years ended September 30, 2017. Additional information and provisions regarding the NYSE American requirements are found in Part 10 of its Company Guide.
CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization (CRO) responsible for data management of this Phase 3 study.
The Vienna, Virginia-based company said it had a loss of 36 cents per share. The cancer immunotherapy company posted revenue of $104,200 in the period. Its adjusted revenue was $104,000. In the final minutes ...
CEL-SCI Corporation today reported financial results for the quarter ended June 30, 2018. The Company also reported key clinical and corporate developments achieved during the quarter.
CEL-SCI Corporation (NYSE American: CVM) reported on a communication received today from the staff of the NYSE American, its current listing exchange, that it considered the Company to be noncompliant with certain listing requirements based on its quarterly report for the period ended March 31, 2018. The Company has been given the opportunity to maintain its listing by submitting a plan of compliance by August 13, 2018. This plan must advise of actions the Company has taken or will take to regain compliance with the continued listing standards by January 14, 2019.
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of MabVax as well as Cel-SCI Corporation were on a gaining frenzy in Monday's trading session as each company presented positive developments. MabVax shares rose on the news that the company has signed an asset acquisition and related agreements with Boehringer Ingelheim. Shares of CEL-SCI Corporation were heading higher after the company issued a positive shareholder letter.
New entrant Biotricity (BTCY) is jumping into the same market with a potentially superior product and under-appreciated market valuation. BTCY expects to be prepared with two more products in the next 6-9 months, and they could all be on the market by the end of 2019. NEW YORK, NY / ACCESSWIRE / July 10, 2018 / With their latest investor update, Biotricity Inc. (BTCY) just dropped a major hint that most investors have been missing so far... key product updates are coming later this year.
CEL-SCI Corporation (NYSE American:CVM) today issued a letter to its shareholders. We have won the arbitration against the clinical research organization (CRO) inVentiv that ran our Phase 3 head and neck cancer study from 2011-2013. It has now been confirmed by the arbitration that inVentiv was the cause of the multi-year delay in our Phase 3 clinical trial in head and neck cancer.
CEL-SCI Corporation (NYSE American: CVM) today announced that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors. The Company has received gross proceeds of approximately $5 million. CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival.
CEL-SCI Corporation (NYSE American: CVM) today announced it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $5 million in a registered direct offering. In connection with the offering, CEL-SCI will issue approximately 3,900,000 registered shares of common stock at a purchase price of $1.30 per share. Concurrently in a private placement, the Company will issue to the investors warrants to purchase up to 3,900,000 shares of its common stock.
CEL-SCI Corporation , in response to shareholder questions, updates its shareholders on the amount of money received from warrant exercises since April 1, 2018. Since that time CEL-SCI has received $2,133,677 through the exercise of warrants by investors to purchase the Company's common stock.
CEL-SCI Corporation (NYSE American: CVM) announced today that after a four and a half year battle a decision has been delivered by the arbitrator in CEL-SCI's arbitration suit against clinical development giant inVentiv, now part of Syneos Health (SYNH). The arbitrator ruled that inVentiv materially breached its contract with CEL-SCI.
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. We expect two very important events for our Company: 1) we anticipate a final resolution this month of the ongoing arbitration brought by CEL-SCI against its former contract research organization (CRO) for its pivotal Phase 3 head and neck cancer trial and 2) the final read-out of our pivotal Phase 3 head and neck cancer trial. Closing arguments in the arbitration suit against the former CRO were concluded on April 25, 2018, and the arbitrator indicated he would render his judgement in the matter within 60 days of the conclusion of closing arguments.